FOXM1 and kidney cancer: Our microarray data indicated FOXM1 pathway disruption, and we detected loss of phospho‐ and/or total FOXM1 protein levels with OTS514 treatment in every cell line examined, consistent with a previous report in kidney cancer cells.24 Additionally, levels of FOXO3 were seen to increase with higher concentrations of OTS514 followed by an eventual decrease when indications of PARP cleavage appeared.